CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis.
Saved in:
| Title: | CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis. |
|---|---|
| Authors: | Ji, Danyang1 (AUTHOR), Luo, Yang1 (AUTHOR), Wang, Jiayu1 (AUTHOR), Chen, Shanshan1 (AUTHOR), Lan, Bo1 (AUTHOR), Ma, Fei1 (AUTHOR), Xu, Binghe1 (AUTHOR) xubinghe@medmail.com.cn, Fan, Ying1 (AUTHOR) fanyingfy@medmail.com.cn |
| Source: | BMC Cancer. 8/29/2023, Vol. 23 Issue 1, p1-11. 11p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 170898372 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Ji%2C+Danyang%22">Ji, Danyang</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Luo%2C+Yang%22">Luo, Yang</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Wang%2C+Jiayu%22">Wang, Jiayu</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Chen%2C+Shanshan%22">Chen, Shanshan</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lan%2C+Bo%22">Lan, Bo</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ma%2C+Fei%22">Ma, Fei</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Xu%2C+Binghe%22">Xu, Binghe</searchLink><relatesTo>1</relatesTo> (AUTHOR)<i> xubinghe@medmail.com.cn</i><br /><searchLink fieldCode="AR" term="%22Fan%2C+Ying%22">Fan, Ying</searchLink><relatesTo>1</relatesTo> (AUTHOR)<i> fanyingfy@medmail.com.cn</i> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22BMC+Cancer%22">BMC Cancer</searchLink>. 8/29/2023, Vol. 23 Issue 1, p1-11. 11p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=170898372 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1186/s12885-023-11290-7 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 11 StartPage: 1 Titles: – TitleFull: CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Ji, Danyang – PersonEntity: Name: NameFull: Luo, Yang – PersonEntity: Name: NameFull: Wang, Jiayu – PersonEntity: Name: NameFull: Chen, Shanshan – PersonEntity: Name: NameFull: Lan, Bo – PersonEntity: Name: NameFull: Ma, Fei – PersonEntity: Name: NameFull: Xu, Binghe – PersonEntity: Name: NameFull: Fan, Ying IsPartOfRelationships: – BibEntity: Dates: – D: 29 M: 08 Text: 8/29/2023 Type: published Y: 2023 Identifiers: – Type: issn-print Value: 14712407 Numbering: – Type: volume Value: 23 – Type: issue Value: 1 Titles: – TitleFull: BMC Cancer Type: main |
| ResultId | 1 |
